FLORIDA!A MEDICAID' Better Health Care for all Floridians. May

Transcription

1 CHARLIE CRIST GOVERNOR FLORIDA!A MEDICAID' Better Health Care for all Floridians HOllY BENSON SECRETARY May Policy Transmittal: HMO Policy Transmittal: PS RE: Year Thrcc PerFormance Measures Dear Medicaid Health Plan: This policy transmittal serves as notice that the Agency For Health Care Administration (Agency) has revised the Year Three PerFormance Measures to be submitted in accordance with the specifications in this transmittal and its related attachments. Section VIII. Quality Management, A.3.c. (limos and Reform and non-reform Fee-For-Service PSNs) and A.3.b. (non-reform Capitated PSNs) permit the Agency to modify performance measure reporting requirements with sixty (60) days advance notice. Altachment I, ivledicaid HMO and P N Specifications/or Pelformance Measures, is a list ofthe performance measures due to the Agency each year. You will no longer need to refercnce the previous years' policy transmittals to locate the most recent list of performance mea ure. The Ageney has provided notations if measures are new or have been revised From previou years and has included a column indicating the year of the HEDIS ational Means and Pereentiles that will be used as the performance benchmark For each measure. Altachment 2. ivledicaid HMO and PSN Pelforll1ance Measures. Version 2009, i a consolidated document listing all specifications For Agency-Defined Measures. Because Year Three is the final year of the Agency's phase-in schedule for performance measures, this list is a consolidated list with all measures that must be reported annually. Attachment 2 also includes an EXCEL chart exhibit (Exhibit A) that provides ICD-9-CM codes and medication information. This chart will be helpful to you regarding the performance measure specifications related to IIiV and/or AIDS. This policy transmittal serves to notice both Reform and on-reform health plans of the required perf0n11ance measures. In the event that a performance measure is not applicable because it measures a Reform-only benefit or because the health plan does not cover the service. the health plan should indicate "NB" when reporting that measure Mahan Drive, MS# a Tallahassee, Florida Visit AHCA online at

2 Policy Transmittal: HMO Policy Transmittal: PSN May 26, 2009 Page Two If you havc any questions or require furthcr clarification, please do not hesitate to contact Deborah Mc amara of my staff at I11cnamard(aahca.myllorida.com or (850) CDS/dm Enclosurcs inccrely, ~~ Carlton D. S~ Dcputy Secretary for Medicaid

3 Attachment 1 Medicaid HMO and PSN Performance Measures Version 2009 HEDIS Note Benchmark Year 1 Adolescent Well Care Visits (AWC) 2 Adults Access to Preventive /Ambulatory Health Services (AAP) 3 Ambulatory Care (AMB) 4 Annual Dental Visits (ADV) 5 Antidepressant Medication Management (AMM) 6 BMI Assessment (ABA) 7 Breast Cancer Screening (BCS) 8 Cervical Cancer Screening (CCS) 9 Childhood Immunization Status (CIS) 10 Comprehensive Diabetes Care (CDC) Without Blood Pressure Measure 11 Controlling High Blood Pressure (CBP) 12 Follow-up Care for Children Prescribed ADHD Medication (ADD) 13 Frequency of Ongoing Prenatal Care (FPC) 14 Lead Screening in Children (LSC) 15 Mental Health Utilization Inpatient, Intermediate, & Ambulatory Services (MPT) 16 Persistence of Beta-Blocker Treatment after a Heart Attack (PBH) 17 Prenatal and Postpartum Care (PPC) 18 Use of Appropriate Medications for People With Asthma (ASM) 19 Well-Child Visits in the First 15 Months of Life (W15) 20 Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34) Agency-Defined Measures HEDIS 2007 HEDIS 2008 N/A HEDIS 2007 HEDIS 2008 new HEDIS 2009 HEDIS 2008 HEDIS 2007 HEDIS 2008 HEDIS 2007 HEDIS 2007 HEDIS 2009 HEDIS 2008 HEDIS 2008 N/A HEDIS 2009 HEDIS 2007 HEDIS 2008 HEDIS 2007 HEDIS Follow-Up after Hospitalization for Mental Illness (FHM) updated Mental Health Readmission Rate (RER) Lipid Profile Annually (LPA) 2009 updated /21/09

4 Attachment 1 Medicaid HMO and PSN Performance Measures Version 2009 Use of Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARB) Therapy (ACE) Use of Beta Agonist (UBA) Frequency of HIV Disease Monitoring Lab Tests (CD4 and VL) Highly Active Anti-Retroviral Treatment (HAART) HIV-Related Medical Visits (HIVV) Percentage of Enrollees Participating in Disease Management Program (DM) 2009 updated 2008 updated 2010 new 2010 new 2010 new N/A Prior Year Deleted Measures - Body Weight Monitoring and / Loss (includes BMI) deleted - Medication Regimen Adherence deleted - Foot Exam Annually deleted - Blood Glucose Self-Monitoring deleted - Asthma Action Plan deleted - CD4 Test Performed and Results deleted - Viral Load Test Performed and Results deleted - Smoking Cessation deleted 4/21/09

5 Attachment 2 Medicaid HMO and PSN Specifications for Performance Measures Follow-up after Hospitalization for a Mental Illness (FHM) Description: The percent of enrollees who were hospitalized for a mental health diagnosis and were discharged to the community from an acute care facility and were seen on an outpatient basis by a mental health practitioner within seven days and within 30 days. Age/Gender: 6 years and older as of the date of discharge. Data Collection Method: Administrative Data. No sampling allowed. Continuous Enrollment: Continuously enrolled for 30 days following discharge. Exclusions: Enrollees who died, enrollees who were re-admitted within 7 days of discharge, or enrollees whose discharges were followed by readmission or direct transfer to a Statewide Inpatient Psychiatric Program (SIPP), a readmission or direct transfer to a Department of Juvenile Justice or Child Welfare Behavioral Health Overlay Service facility, members who receive Florida Assertive Community Treatment services, and members who are admitted to hospice, nursing facilities, state mental health facilities, and correctional institutions within the 7 days after discharge. Administrative Specification Numerator One: 7 Days: FHM-7 Denominator: Enrollees who were discharged to the community from an acute care facility (inpatient or crisis stabilization unit) who had a discharge diagnosis of ICD-9-CM codes through , through 298.9, through 301.9, 302.7, through and through 314.9, 315.3, , 315.5, 315.8, and who were continuously enrolled for 7 days following discharge. Numerator: An outpatient follow-up encounter with a mental health practitioner (see definition below) up to seven days after hospital discharge. Numerator Two: 30 Days: FHM-30 Denominator: Enrollees who were discharged to the community from an acute care facility (inpatient or crisis stabilization unit) who had a discharge diagnosis of ICD-9-CM codes through , through 298.9, through 301.9, 302.7, through and through 314.9, 315.3, , 315.5, 315.8, and who were continuously enrolled for 30 days following discharge. Numerator: An outpatient follow-up encounter with a mental health practitioner (see definition below) up to thirty days after hospital discharge. Page 1 of 11 04/14/2009

6 Allowable Encounter/Claim Codes Attachment 2 Medicaid HMO and PSN Specifications for Performance Measures UB Revenue CPT HCPCS 0513, 0910, 0912, 0914, , 90801, 90802, , 90847, 90849, 90853, 90855, 90862, 99201, 99202, 99204, 99205, , G0154 HE*, H0031 HO, H0031 TS, H0035, H0046, H2000 HO, H2000 HP, H2010 HE, H2010 HO, H2010 HQ, H2012, H2017, H2019 HK, H2019 HQ, H2019 HR, H2019 HM, H2019 HN, H2019 HO, S9127, T1001*, T1015, T1015 HE, T1023 HE *Must be provided by an RN who meets the definition of a mental health practitioner Mental Health Practitioner: A Florida licensed MD or doctor of osteopathy (DO) who is certified as a psychiatrist or child psychiatrist by the American Medical Specialties Board of Psychiatry and Neurology or by the American Osteopathic Board of Neurology and Psychiatry; or, if not certified, who successfully completed an accredited program of graduate medical or osteopathic education in psychiatry or child psychiatry. A Florida Licensed Psychologist or a doctoral level psychologist practicing under the auspices of a community mental health center and being supervised by a licensed psychologist. An individual who is certified in clinical social work by the American Board of Examiners; who is listed on the National Association of Social Worker s Clinical Register; or who is a Florida Licensed Clinical Social Worker; or who is a masters level social worker practicing under the auspices of a community mental health center and being supervised by a licensed clinical social worker. A Florida-licensed registered nurse (RN) who is certified by the American Nurses Credentialing Center (a subsidiary of the American Nurses Association) as a psychiatric nurse or mental health clinical nurse specialist, or who has a master s degree in nursing with a specialization in psychiatric/ mental health and two years of supervised clinical experience. A Florida-licensed Marriage and Family Therapist or a masters level marriage and family therapist practicing under the auspices of a community mental health center and being supervised by a Licensed Marriage and Family Therapist. A Florida Licensed Mental Health Counselor or a masters level counselor practicing under the auspices of a community mental health center and being supervised by a Licensed Mental Health Counselor. Page 2 of 11 04/14/2009

7 Attachment 2 Medicaid HMO and PSN Specifications for Performance Measures Mental Health Readmission Rate (RER) Description: The percent of enrollees who were hospitalized for a mental health diagnosis and were discharged to the community from an acute care facility and were readmitted for a mental health diagnosis within 30 days. Age/Gender: 6 years and older as of the date of discharge. Data Collection Method: Administrative Data. No sampling allowed. Continuous Enrollment: Continuously enrolled for 30 days following discharge. Exclusions: Enrollees who died, or enrollees whose discharges were followed by readmission or direct transfer to a Statewide Inpatient Psychiatric Program (SIPP), a readmission or direct transfer to a Department of Juvenile Justice or Child Welfare Behavioral Health Overlay Service facility, members who receive Florida Assertive Community Treatment Services, and members who are admitted to nursing facilities, state mental health treatment facilities, correctional institutions and hospice programs within the 30 days after discharge. Administrative Specification Denominator: Enrollees who were discharged to the community from an acute care facility (inpatient or crisis stabilization unit) who had a discharge diagnosis of ICD-9-CM codes through , through 298.9, through 301.9, 302.7, through and through 314.9, 315.3, , 315.5, 315.8, and who were continuously enrolled for 30 days following discharge. Numerator: Readmission to an acute care facility (inpatient or crisis stabilization unit) with a diagnosis of ICD-9-CM codes through , through 298.9, through 301.9, 302.7, through and through 314.9, 315.3, , 315.5, 315.8, and within 30 days following discharge. Lipid Profile Annually (LPA) Description: The percentage of members 18 to 85 years of age who had a diagnosis of hypertension and who had a lipid profile during the measurement year that includes total cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides. Ages: 18 to 85 years of age as of December 31 of the measurement year. Data Collection Method: Administrative or Hybrid. Page 3 of 11 04/14/2009

8 Attachment 2 Medicaid HMO and PSN Specifications for Performance Measures Continuous Enrollment: In health plan for the measurement year with no more than a one month gap in coverage. Administrative Specification Denominator: Enrollees with hypertension as defined by the inclusion criteria for the HEDIS measure, Controlling High Blood Pressure, most recent edition. -OR- Numerator: Those beneficiaries in the denominator who have had a lipid profile in the measurement year that includes total cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides. CPT Codes LOINC Codes Lipid Profile , , , Cholesterol, Total , , , HDL Cholesterol , Triglycerides , , , , , Hybrid Specification Denominator: A systematic sample drawn from the eligible population following the HEDIS Guidelines for Calculations and Sampling with a sample size of 411. Numerator: Refer to the Administrative Specification above. At a minimum, documentation in the medical record must include a note indicating the date on which the lipid profile (or its component parts) was performed. Use of Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARB) Therapy (ACE) Description: The percentage of members 18 years and older during the measurement year who were diagnosed with congestive heart failure, and who have at least one prescription filled for angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) during the measurement year. Page 4 of 11 04/14/2009

9 Attachment 2 Medicaid HMO and PSN Specifications for Performance Measures Eligible Population: Enrollees with a congestive heart failure diagnosis as determined by the method below. Diagnosis: Identify members as having heart failure (HF) who met at least one of the following criteria, during the measurement year: At least one outpatient visit with any HF diagnosis (Table HFM-A), Or At least one acute inpatient visit with any HF diagnosis (Table HFM-B) Table HFM-A: Codes to Identify Outpatient Visit for Heart Failure ICD-9-CM Diagnosis CPT UB Revenue , , , , , , , , , 428.0, 428.1, , , , , , , , , , , , , WITH , , , , , , , , , 99411, 99412, 99420, x, , , 057x- 059x, 077x, 0982, 0983 OR CPT Category II LVEF <40% 3021F Table HFM-B: Codes to Identify Inpatient Visit for Heart Failure ICD-9-CM Diagnosis CPT UB Revenue , , , , , , , , , 428.0, 428.1, , , , , , , , , , , , , WITH , , 99238, 99239, , , Ages: 18 years and older as of December 31 of the measurement year. Data Collection Method: Administrative Data. No sampling allowed. 010x, , 0119, , 0129, , 0139, , 0149, , 0159, 016x, 020x- 022x, 072x, 0987 Continuous enrollment: In health plan for six months or more during the measurement year with a gap of no more than one month. Administrative Specification Denominator: The eligible population. Page 5 of 11 04/14/2009

10 Attachment 2 Medicaid HMO and PSN Specifications for Performance Measures Numerator: All members in the denominator population with at least one prescription filled during the measurement year for a medication from the therapeutic classes specified above. ACE inhibitors are defined with therapeutic class codes A4D and A4K. ARBs are defined with therapeutic class code A4F. Use of Beta Agonist (UBA) Description: The percentage of members 5 to 56 years of age during the measurement year who were identified as having persistent asthma and who had prescriptions for beta agonist medications filled during the measurement year. Eligible Population: Enrollees with asthma as defined by the inclusion criteria for the HEDIS measure, Use of Appropriate Medications for People with Asthma, most recent edition. Ages: 15 to 56 years as of December 31 of the measurement Year. Results should be stratified into three age groups and an overall total rate: 5 to 9 years old 10 to 17 years old years old Total (Calculate total as the sum of the numerators for each age group divided by sum of the denominators for each age group). Data Collection Method: Administrative data. No sampling allowed. Continuous Enrollment: In health plan for six months or more during the measurement year with no more than a one month gap in coverage. Administrative Specification Denominator: The eligible population. Numerator: All members in the denominator with at least one prescription for beta agonist medications filled during the measurement year. Beta agonist medications are defined with the following therapeutic class code J5D and J5G. Frequency of HIV Disease Monitoring Lab Tests (CD4) and (VL) Description: The frequency of HIV disease monitoring lab tests performed in a calendar year. Eligible Population: Enrollees with HIV/AIDS as identified by ICD-9-CM diagnosis code 042, , or V08. Page 6 of 11 04/14/2009

11 Attachment 2 Medicaid HMO and PSN Specifications for Performance Measures Ages: No age limitations. Data Collection Method: Administrative Data. No sampling allowed. Continuous Enrollment: Continuously enrolled in the health plan a minimum of 9 months throughout the measurement year with gaps in enrollment permitted. Administrative Specification Frequency of CD4 T-cell Tests performed (CD4): Denominator: Total number of enrollees with HIV/AIDS in the health plan. Numerator: Three separate numerators are calculated: a. Enrollees with >= 3 tests performed in a 12 month period. b. Enrollees with 2 tests performed in 12 month period. c. Enrollees with 1 test performed in 12 month period. Frequency of Viral Load tests performed (VL) Denominator: Total number of enrollees with HIV/AIDS in health plan. Numerator: Three separate numerators are calculated: a. Enrollees with >= 3 tests performed in a 12 month period. b. Enrollees with 2 tests performed in 12 month period. c. Enrollees with 1 test performed in 12 month period. Highly Active Anti-Retroviral Treatment (HAART) Description: The percentage of enrollees with an AIDS diagnosis that have been prescribed a Highly Active Anti-Retroviral Treatment drug. Eligible Population: Enrollees with AIDS as identified by ICD-9-CM diagnosis code 042. Ages: No age limitations. Data Collection Method: Administrative Data. No sampling allowed. Continuous Enrollment: Continuously enrolled in the health plan a minimum of 9 months through-out the measurement year with gaps in enrollment permitted. Administrative Specification Page 7 of 11 04/14/2009

12 Attachment 2 Medicaid HMO and PSN Specifications for Performance Measures Denominator: Number of enrollees in the plan diagnosed with AIDS. Numerator: Number of enrollees who were prescribed a HAART regimen (see HIV/AIDS Attachment) within the measurement year. HIV-Related Medical Visits (HIVV) Description: The percentage of enrollees with HIV/AIDS who were seen by a physician, Physicians Assistant or Advanced Registered Nurse Practitioner for an HIV related medical visit (see HIV/AIDS Attachment) within the measurement year. Eligible Population: Enrollees with HIV/AIDS as identified by ICD-9-CM diagnosis code 042, , or V08. Ages: No age limitations. Data Collection Method: Administrative Data. No sampling allowed. Continuous Enrollment: Continuously enrolled in the health plan a minimum of 9 months through-out the measurement year with gaps in enrollment permitted. Administrative Specification Denominator: Number of enrollees with HIV/AIDS in the plan. Numerator: Three separate numerators are calculated: a. Enrollees who were seen twice in measurement year, <= 6 months apart. b. Enrollees who were seen more than twice in measurement year. c. Enrollees who were seen once in the measurement year. Percentage of Enrollees Participating in Disease Management Programs (DM) Description: The percentage of health plan enrollees with a specified disease state who are enrolled in the plan s disease management program. Eligible Population: All enrollees with the following diagnoses: 1. HIV/AIDS 2. Congestive Heart Failure 3. Diabetes Page 8 of 11 04/14/2009

13 4. Hypertension 5. Asthma Ages: No age limitations. Attachment 2 Medicaid HMO and PSN Specifications for Performance Measures Data Collection Method: Administrative Data. No sampling allowed. Continuous Enrollment: Continuously enrolled for at least four months of the measurement year with no more than one month gap in coverage. Exclusions: Enrollees with multiple disease states may be counted in the denominator for one disease state only. The enrollee should be categorized by their highest disease state, as listed in hierarchical order above. Administrative Specification Numerator One: HIV/AIDS (HIV) Denominator: Enrollees with HIV/AIDS as identified by ICD-9-CM diagnosis code 042 or V08. Numerator: Those enrollees in the denominator who were enrolled in the disease management program for HIV/AIDS at least two months during the measurement year. Numerator Two: Congestive Heart Failure (CHF) Denominator: Members are identified for the eligible population through diagnosis criteria. Diagnosis: Identify members as having heart failure (HF) who met at least one of the following criteria, during the measurement year. At least one outpatient visit with any HF diagnosis (Table HFM-A), Or At least one acute inpatient visit with any HF diagnosis (Table HFM-B) Table HFM-A: Codes to Identify Outpatient Visit for Heart Failure ICD-9-CM Diagnosis CPT UB Revenue , , , , , , , , , 428.0, 428.1, , , , , , , , , , , , , OR WITH , , , , , , , , , 99411, 99412, 99420, x, , , 057x- 059x, 077x, 0982, 0983 Page 9 of 11 04/14/2009

14 Attachment 2 Medicaid HMO and PSN Specifications for Performance Measures CPT Category II LVEF <40% 3021F Table HFM-B: Codes to Identify Inpatient Visit for Heart Failure ICD-9-CM Diagnosis CPT UB Revenue , , , , , , , , , 428.0, 428.1, , , , , , , , , , , , , WITH , , 99238, 99239, , , x, , 0119, , 0129, , 0139, , 0149, , 0159, 016x, 020x- 022x, 072x, 0987 Numerator: Those enrollees in the denominator who were enrolled in the disease management program for congestive heart failure two or more months during the measurement year. Numerator Three: Diabetes (DIA) Denominator: Enrollees with diabetes as defined by the inclusion criteria for the HEDIS measure, Comprehensive Diabetes Care, most recent edition. Numerator: Those enrollees in the denominator who were enrolled in the disease management program for diabetes at least two months during the measurement year. Numerator Four: Hypertension (HTN) Denominator: Enrollees with hypertension as defined by the inclusion criteria for the HEDIS measure, Controlling High Blood Pressure, most recent edition. Numerator: Those enrollees in the denominator who were enrolled in the disease management program for hypertension at least two months during the measurement year. Numerator Five: Asthma (AST) Denominator: Enrollees with asthma as defined by the inclusion criteria for the HEDIS measure, Use of Appropriate Medications for People with Asthma, most recent edition. Numerator: Those enrollees in the denominator who were enrolled in the disease management program for asthma at least two months during the measurement year. Optional Reporting: Other Disease States Page 10 of 11 04/14/2009

15 Attachment 2 Medicaid HMO and PSN Specifications for Performance Measures If the health plan operates disease management programs for disease states other than those specified above, the health plan may report the percentage of enrolled enrollees as an optional numerator(s) using the specification format for the required disease states. The health plan must provide a notation labeling the disease state of the optional program. Page 11 of 11 04/14/2009

16

17 HAART NDC Drug Name Drug Generic Name HIC REYATAZ 300 MG CAPSULE ATAZANAVIR SULFATE W5C REYATAZ 100 MG CAPSULE ATAZANAVIR SULFATE W5C REYATAZ 150 MG CAPSULE ATAZANAVIR SULFATE W5C REYATAZ 200 MG CAPSULE ATAZANAVIR SULFATE W5C INVIRASE 500 MG TABLET SAQUINAVIR MESYLATE W5C INVIRASE 200 MG CAPSULE SAQUINAVIR MESYLATE W5C FORTOVASE 200 MG SOFTGEL CAP SAQUINAVIR W5C CRIXIVAN 100 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 200 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 200 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 333 MG CAPSULE INDINAVIR SULFATE W5C NORVIR 80 MG/ML SOLUTION RITONAVIR W5C NORVIR 100 MG SOFTGEL CAP RITONAVIR W5C NORVIR 100 MG SOFTGEL CAP RITONAVIR W5C NORVIR 100 MG CAPSULE RITONAVIR W5C NORVIR 100 MG CAPSULE RITONAVIR W5C AGENERASE 150 MG CAPSULE AMPRENAVIR/VITAMIN E W5C AGENERASE 50 MG CAPSULE AMPRENAVIR/VITAMIN E W5C AGENERASE 15 MG/ML ORAL SOLN AMPRENAVIR/VITAMIN E/PROP W5C LEXIVA 700 MG TABLET FOSAMPRENAVIR CALCIUM W5C LEXIVA 50 MG/ML SUSPENSION FOSAMPRENAVIR CALCIUM W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C LEXIVA 700 MG TABLET FOSAMPRENAVIR CALCIUM W5C LEXIVA 700 MG TABLET FOSAMPRENAVIR CALCIUM W5C REYATAZ 150 MG CAPSULE ATAZANAVIR SULFATE W5C REYATAZ 150 MG CAPSULE ATAZANAVIR SULFATE W5C REYATAZ 300 MG CAPSULE ATAZANAVIR SULFATE W5C REYATAZ 300 MG CAPSULE ATAZANAVIR SULFATE W5C VIRACEPT 625 MG TABLET NELFINAVIR MESYLATE W5C NORVIR 100 MG SOFTGEL CAP RITONAVIR W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C REYATAZ 200 MG CAPSULE ATAZANAVIR SULFATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C INVIRASE 200 MG CAPSULE SAQUINAVIR MESYLATE W5C Page 1

18 HAART INVIRASE 200 MG CAPSULE SAQUINAVIR MESYLATE W5C INVIRASE 200 MG CAPSULE SAQUINAVIR MESYLATE W5C INVIRASE 200 MG CAPSULE SAQUINAVIR MESYLATE W5C NORVIR 100 MG CAPSULE RITONAVIR W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C FORTOVASE 200 MG SOFTGEL CAP SAQUINAVIR W5C FORTOVASE 200 MG SOFTGEL CAP SAQUINAVIR W5C NORVIR 80 MG/ML SOLUTION RITONAVIR W5C NORVIR 100 MG CAPSULE RITONAVIR W5C AGENERASE 150 MG CAPSULE AMPRENAVIR/VITAMIN E W5C REYATAZ 150 MG CAPSULE ATAZANAVIR SULFATE W5C REYATAZ 200 MG CAPSULE ATAZANAVIR SULFATE W5C LEXIVA 700 MG TABLET FOSAMPRENAVIR CALCIUM W5C NORVIR 100 MG SOFTGEL CAP RITONAVIR W5C INVIRASE 500 MG TABLET SAQUINAVIR MESYLATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C INVIRASE 200 MG CAPSULE SAQUINAVIR MESYLATE W5C INVIRASE 200 MG CAPSULE SAQUINAVIR MESYLATE W5C INVIRASE 200 MG CAPSULE SAQUINAVIR MESYLATE W5C NORVIR 100 MG CAPSULE RITONAVIR W5C NORVIR 100 MG SOFTGEL CAP RITONAVIR W5C NORVIR 100 MG CAPSULE RITONAVIR W5C NORVIR 100 MG SOFTGEL CAP RITONAVIR W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C FORTOVASE 200 MG SOFTGEL CAP SAQUINAVIR W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C REYATAZ 200 MG CAPSULE ATAZANAVIR SULFATE W5C REYATAZ 150 MG CAPSULE ATAZANAVIR SULFATE W5C LEXIVA 700 MG TABLET FOSAMPRENAVIR CALCIUM W5C VIRACEPT 625 MG TABLET NELFINAVIR MESYLATE W5C REYATAZ 300 MG CAPSULE ATAZANAVIR SULFATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C CRIXIVAN 400 MG CAPSULE INDINAVIR SULFATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C Page 2

19 HAART VIRACEPT POWDER NELFINAVIR MESYLATE W5C VIRACEPT 625 MG TABLET NELFINAVIR MESYLATE W5C VIRACEPT 250 MG TABLET NELFINAVIR MESYLATE W5C REYATAZ 150 MG CAPSULE ATAZANAVIR SULFATE W5C VIREAD 300 MG TABLET TENOFOVIR DISOPROXIL FUM W5I VIREAD 300 MG TABLET TENOFOVIR DISOPROXIL FUM W5I VIREAD 300 MG TABLET TENOFOVIR DISOPROXIL FUM W5I VIREAD 300 MG TABLET TENOFOVIR DISOPROXIL FUM W5I VIREAD 300 MG TABLET TENOFOVIR DISOPROXIL FUM W5I VIREAD 300 MG TABLET TENOFOVIR DISOPROXIL FUM W5I ZERIT 15 MG CAPSULE STAVUDINE W5J ZERIT 20 MG CAPSULE STAVUDINE W5J ZERIT 30 MG CAPSULE STAVUDINE W5J ZERIT 40 MG CAPSULE STAVUDINE W5J ZERIT 1 MG/ML SOLUTION STAVUDINE W5J HIVID MG TABLET ZALCITABINE W5J HIVID MG TABLET ZALCITABINE W5J ZIDOVUDINE 300 MG TABLET ZIDOVUDINE W5J RETROVIR IV INFUSION VIAL ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 10 MG/ML SYRUP ZIDOVUDINE W5J VIDEX 100 MG PACKET DIDANOSINE/SODIUM CITRATE W5J VIDEX 167 MG PACKET DIDANOSINE/SODIUM CITRATE W5J VIDEX 250 MG PACKET DIDANOSINE/SODIUM CITRATE W5J VIDEX 2 GM PEDIATRIC SOLN DIDANOSINE W5J VIDEX 4 GM PEDIATRIC SOLN DIDANOSINE W5J VIDEX 25 MG TABLET CHEWABLE DIDANOSINE/CALCIUM CARB/M W5J VIDEX 50 MG TABLET CHEWABLE DIDANOSINE/CALCIUM CARB/M W5J VIDEX 100 MG TABLET CHEWABLE DIDANOSINE/CALCIUM CARB/M W5J VIDEX 150 MG TABLET CHEWABLE DIDANOSINE/CALCIUM CARB/M W5J VIDEX 200 MG TABLET CHEWABLE DIDANOSINE/CALCIUM CARB/M W5J VIDEX EC 125 MG CAP SA DIDANOSINE W5J VIDEX EC 200 MG CAP SA DIDANOSINE W5J VIDEX EC 250 MG CAP SA DIDANOSINE W5J VIDEX EC 400 MG CAP SA DIDANOSINE W5J ZIDOVUDINE 300 MG TABLET ZIDOVUDINE W5J RETROVIR IV INFUSION VIAL ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 10 MG/ML SYRUP ZIDOVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 10 MG/ML ORAL SOLN LAMIVUDINE W5J RETROVIR 300 MG TABLET ZIDOVUDINE W5J ZIAGEN 300 MG TABLET ABACAVIR SULFATE W5J ZIAGEN 300 MG TABLET ABACAVIR SULFATE W5J ZIAGEN 20 MG/ML SOLUTION ABACAVIR SULFATE W5J EPIVIR 300 MG TABLET LAMIVUDINE W5J STAVUDINE 15 MG CAPSULE STAVUDINE W5J STAVUDINE 20 MG CAPSULE STAVUDINE W5J STAVUDINE 30 MG CAPSULE STAVUDINE W5J STAVUDINE 40 MG CAPSULE STAVUDINE W5J Page 3

20 HAART DIDANOSINE 200 MG DR CAPSULE DIDANOSINE W5J DIDANOSINE 250 MG DR CAPSULE DIDANOSINE W5J DIDANOSINE 400 MG DR CAPSULE DIDANOSINE W5J ZIDOVUDINE 300 MG TABLET ZIDOVUDINE W5J STAVUDINE 15 MG CAPSULE STAVUDINE W5J STAVUDINE 20 MG CAPSULE STAVUDINE W5J STAVUDINE 30 MG CAPSULE STAVUDINE W5J STAVUDINE 40 MG CAPSULE STAVUDINE W5J EPIVIR 300 MG TABLET LAMIVUDINE W5J EPIVIR 10 MG/ML ORAL SOLN LAMIVUDINE W5J ZERIT 40 MG CAPSULE STAVUDINE W5J ZIAGEN 300 MG TABLET ABACAVIR SULFATE W5J ZIAGEN 300 MG TABLET ABACAVIR SULFATE W5J VIDEX EC 400 MG CAP SA DIDANOSINE W5J EMTRIVA 200 MG CAPSULE EMTRICITABINE W5J DIDANOSINE 400 MG DR CAPSULE DIDANOSINE W5J ZERIT 30 MG CAPSULE STAVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 10 MG/ML SYRUP ZIDOVUDINE W5J RETROVIR 10 MG/ML SYRUP ZIDOVUDINE W5J RETROVIR 300 MG TABLET ZIDOVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J VIDEX 100 MG TABLET CHEWABLE DIDANOSINE/CALCIUM CARB/M W5J HIVID MG TABLET ZALCITABINE W5J HIVID MG TABLET ZALCITABINE W5J ZERIT 30 MG CAPSULE STAVUDINE W5J ZERIT 40 MG CAPSULE STAVUDINE W5J ZERIT 40 MG CAPSULE STAVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J Page 4

21 HAART VIDEX 100 MG TABLET CHEWABLE DIDANOSINE/CALCIUM CARB/M W5J VIDEX 100 MG TABLET CHEWABLE DIDANOSINE/CALCIUM CARB/M W5J EPIVIR 10 MG/ML ORAL SOLN LAMIVUDINE W5J RETROVIR 10 MG/ML SYRUP ZIDOVUDINE W5J HIVID MG TABLET ZALCITABINE W5J VIDEX 4 GM PEDIATRIC SOLN DIDANOSINE W5J RETROVIR 300 MG TABLET ZIDOVUDINE W5J ZIAGEN 300 MG TABLET ABACAVIR SULFATE W5J VIDEX 200 MG TABLET CHEWABLE DIDANOSINE/CALCIUM CARB/M W5J VIDEX EC 400 MG CAP SA DIDANOSINE W5J ZERIT 1 MG/ML SOLUTION STAVUDINE W5J ZIAGEN 20 MG/ML SOLUTION ABACAVIR SULFATE W5J ZERIT 15 MG CAPSULE STAVUDINE W5J ZERIT 20 MG CAPSULE STAVUDINE W5J EPIVIR 300 MG TABLET LAMIVUDINE W5J VIDEX EC 250 MG CAP SA DIDANOSINE W5J EMTRIVA 200 MG CAPSULE EMTRICITABINE W5J DIDANOSINE 250 MG DR CAPSULE DIDANOSINE W5J DIDANOSINE 400 MG DR CAPSULE DIDANOSINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J HIVID MG TABLET ZALCITABINE W5J HIVID MG TABLET ZALCITABINE W5J HIVID MG TABLET ZALCITABINE W5J VIDEX 100 MG TABLET CHEWABLE DIDANOSINE/CALCIUM CARB/M W5J RETROVIR 10 MG/ML SYRUP ZIDOVUDINE W5J ZERIT 40 MG CAPSULE STAVUDINE W5J ZERIT 40 MG CAPSULE STAVUDINE W5J ZERIT 20 MG CAPSULE STAVUDINE W5J ZERIT 15 MG CAPSULE STAVUDINE W5J ZERIT 30 MG CAPSULE STAVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J ZIAGEN 300 MG TABLET ABACAVIR SULFATE W5J ZIAGEN 300 MG TABLET ABACAVIR SULFATE W5J VIDEX EC 400 MG CAP SA DIDANOSINE W5J EMTRIVA 200 MG CAPSULE EMTRICITABINE W5J EPIVIR 300 MG TABLET LAMIVUDINE W5J DIDANOSINE 250 MG DR CAPSULE DIDANOSINE W5J VIDEX EC 250 MG CAP SA DIDANOSINE W5J HIVID MG TABLET ZALCITABINE W5J ZIDOVUDINE 300 MG TABLET ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J Page 5

22 HAART RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J EPIVIR 300 MG TABLET LAMIVUDINE W5J EPIVIR 300 MG TABLET LAMIVUDINE W5J EPIVIR 300 MG TABLET LAMIVUDINE W5J EPIVIR 300 MG TABLET LAMIVUDINE W5J RETROVIR 300 MG TABLET ZIDOVUDINE W5J RETROVIR 300 MG TABLET ZIDOVUDINE W5J RETROVIR 300 MG TABLET ZIDOVUDINE W5J RETROVIR 300 MG TABLET ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J EMTRIVA 200 MG CAPSULE EMTRICITABINE W5J EMTRIVA 10 MG/ML SOLUTION EMTRICITABINE W5J DIDANOSINE 250 MG DR CAPSULE DIDANOSINE W5J DIDANOSINE 250 MG DR CAPSULE DIDANOSINE W5J DIDANOSINE 400 MG DR CAPSULE DIDANOSINE W5J DIDANOSINE 400 MG DR CAPSULE DIDANOSINE W5J ZIDOVUDINE 300 MG TABLET ZIDOVUDINE W5J ZIDOVUDINE 300 MG TABLET ZIDOVUDINE W5J ZIDOVUDINE 50 MG/5 ML SYRUP ZIDOVUDINE W5J ZIDOVUDINE 100 MG CAPSULE ZIDOVUDINE W5J DIDANOSINE 125 MG DR CAPSULE DIDANOSINE W5J DIDANOSINE 200 MG DR CAPSULE DIDANOSINE W5J DIDANOSINE 250 MG DR CAPSULE DIDANOSINE W5J DIDANOSINE 400 MG DR CAPSULE DIDANOSINE W5J ZIDOVUDINE 100 MG CAPSULE ZIDOVUDINE W5J ZIDOVUDINE 50 MG/5 ML SYRUP ZIDOVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J RETROVIR 100 MG CAPSULE ZIDOVUDINE W5J EPIVIR 150 MG TABLET LAMIVUDINE W5J ZERIT 20 MG CAPSULE STAVUDINE W5J RESCRIPTOR 100 MG TABLET DELAVIRDINE MESYLATE W5K RESCRIPTOR 200 MG TABLET DELAVIRDINE MESYLATE W5K VIRAMUNE 50 MG/5 ML SUSP NEVIRAPINE W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K SUSTIVA 50 MG CAPSULE EFAVIRENZ W5K SUSTIVA 100 MG CAPSULE EFAVIRENZ W5K SUSTIVA 200 MG CAPSULE EFAVIRENZ W5K SUSTIVA 600 MG TABLET EFAVIRENZ W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K VIRAMUNE 50 MG/5 ML SUSP NEVIRAPINE W5K SUSTIVA 200 MG CAPSULE EFAVIRENZ W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K VIRAMUNE 50 MG/5 ML SUSP NEVIRAPINE W5K Page 6

23 HAART SUSTIVA 600 MG TABLET EFAVIRENZ W5K SUSTIVA 600 MG TABLET EFAVIRENZ W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K RESCRIPTOR 100 MG TABLET DELAVIRDINE MESYLATE W5K SUSTIVA 200 MG CAPSULE EFAVIRENZ W5K RESCRIPTOR 200 MG TABLET DELAVIRDINE MESYLATE W5K SUSTIVA 600 MG TABLET EFAVIRENZ W5K RESCRIPTOR 200 MG TABLET DELAVIRDINE MESYLATE W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K RESCRIPTOR 200 MG TABLET DELAVIRDINE MESYLATE W5K SUSTIVA 600 MG TABLET EFAVIRENZ W5K INTELENCE 100 MG TABLET ETRAVIRINE W5K VIRAMUNE 200 MG TABLET NEVIRAPINE W5K INTELENCE 100 MG TABLET ETRAVIRINE W5K RESCRIPTOR 100 MG TABLET DELAVIRDINE MESYLATE W5K RESCRIPTOR 200 MG TABLET DELAVIRDINE MESYLATE W5K SUSTIVA 600 MG TABLET EFAVIRENZ W5K SUSTIVA 200 MG CAPSULE EFAVIRENZ W5K COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L TRIZIVIR TABLET ABACAVIR/LAMIVUDINE/ZIDOV W5L TRIZIVIR TABLET ABACAVIR/LAMIVUDINE/ZIDOV W5L EPZICOM TABLET ABACAVIR SULFATE/LAMIVUD W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L EPZICOM TABLET ABACAVIR SULFATE/LAMIVUD W5L EPZICOM TABLET ABACAVIR SULFATE/LAMIVUD W5L TRIZIVIR TABLET ABACAVIR/LAMIVUDINE/ZIDOV W5L TRIZIVIR TABLET ABACAVIR/LAMIVUDINE/ZIDOV W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L TRIZIVIR TABLET ABACAVIR/LAMIVUDINE/ZIDOV W5L EPZICOM TABLET ABACAVIR SULFATE/LAMIVUD W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L Page 7

24 HAART EPZICOM TABLET ABACAVIR SULFATE/LAMIVUD W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L COMBIVIR TABLET LAMIVUDINE/ZIDOVUDINE W5L TRIZIVIR TABLET ABACAVIR/LAMIVUDINE/ZIDOV W5L KALETRA MG TABLET RITONAVIR/LOPINAVIR W5M KALETRA /5 ML ORAL SOLU RITONAVIR/LOPINAVIR W5M KALETRA MG SOFTGEL RITONAVIR/LOPINAVIR W5M KALETRA MG TABLET RITONAVIR/LOPINAVIR W5M KALETRA MG TABLET RITONAVIR/LOPINAVIR W5M KALETRA MG TABLET RITONAVIR/LOPINAVIR W5M KALETRA MG TABLET RITONAVIR/LOPINAVIR W5M KALETRA MG TABLET RITONAVIR/LOPINAVIR W5M KALETRA SOFTGEL RITONAVIR/LOPINAVIR W5M KALETRA ORAL SOLUTION RITONAVIR/LOPINAVIR W5M KALETRA MG TABLET RITONAVIR/LOPINAVIR W5M KALETRA MG SOFTGEL RITONAVIR/LOPINAVIR W5M KALETRA MG TABLET RITONAVIR/LOPINAVIR W5M KALETRA MG TABLET RITONAVIR/LOPINAVIR W5M KALETRA SOFTGEL RITONAVIR/LOPINAVIR W5M KALETRA MG TABLET RITONAVIR/LOPINAVIR W5M FUZEON CONVENIENCE KIT ENFUVIRTIDE W5N FUZEON CONVENIENCE KIT ENFUVIRTIDE W5N FUZEON CONVENIENCE KIT ENFUVIRTIDE W5N TRUVADA TABLET EMTRICITABINE/TENOFOVIR W5O TRUVADA TABLET EMTRICITABINE/TENOFOVIR W5O TRUVADA TABLET EMTRICITABINE/TENOFOVIR W5O TRUVADA TABLET EMTRICITABINE/TENOFOVIR W5O TRUVADA TABLET EMTRICITABINE/TENOFOVIR W5O TRUVADA TABLET EMTRICITABINE/TENOFOVIR W5O TRUVADA TABLET EMTRICITABINE/TENOFOVIR W5O APTIVUS 100 MG/ML SOLUTION TIPRANAVIR/VITAMIN E TPGS W5P APTIVUS 250 MG CAPSULE TIPRANAVIR W5P PREZISTA 300 MG TABLET DARUNAVIR ETHANOLATE W5P PREZISTA 300 MG TABLET DARUNAVIR ETHANOLATE W5P PREZISTA 600 MG TABLET DARUNAVIR ETHANOLATE W5P PREZISTA 300 MG TABLET DARUNAVIR ETHANOLATE W5P Page 8

25 HAART PREZISTA 300 MG TABLET DARUNAVIR ETHANOLATE W5P PREZISTA 300 MG TABLET DARUNAVIR ETHANOLATE W5P PREZISTA 400 MG TABLET DARUNAVIR ETHANOLATE W5P PREZISTA 600 MG TABLET DARUNAVIR ETHANOLATE W5P PREZISTA 75 MG TABLET DARUNAVIR ETHANOLATE W5P SELZENTRY 150 MG TABLET MARAVIROC W5T SELZENTRY 300 MG TABLET MARAVIROC W5T SELZENTRY 150 MG TABLET MARAVIROC W5T SELZENTRY 300 MG TABLET MARAVIROC W5T SELZENTRY 300 MG TABLET MARAVIROC W5T ISENTRESS 400 MG TABLET RALTEGRAVIR POTASSIUM W5U ISENTRESS 400 MG TABLET RALTEGRAVIR POTASSIUM W5U ISENTRESS 400 MG TABLET RALTEGRAVIR POTASSIUM W5U ISENTRESS 400 MG TABLET RALTEGRAVIR POTASSIUM W5U ISENTRESS 400 MG TABLET RALTEGRAVIR POTASSIUM W5U Page 9